Replies to post #150869 on Biotech Values

[Summer2762]

If both arms move to subsequent therapies in same numbers,

That's about true. About %60 of those who progressed used a subsequent therapy.

However, the usage of Zytiga is not the same. 50% vs 40% in favor of enzalutamide which should reflect the later availability of abi.